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Abstract
Cytomegalovirus (CMV) is the most frequent infectious complication following solid organ transplantation (SOT). The virus, is responsible
for both direct (viral syndrome, hepatitis, pneumonitis, colitis, etc.) and indirect effects (rejection, infections by other microorganisms and
graft dysfunction). In this evidence-based guideline we deal with the most important aspects of CMV infection in SOT recipients, including
pre- and post-transplant diagnosis assessment and risk factors, with special emphasis on the prevention and treatment of this viral infection.
Overall, adequate management of CMV infection is a critical aspect of transplant patient care.
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Hot Topics
 Antiviral prophylaxis or preemptive therapy should be used
for the prevention of CMV replication and disease after solid
organ transplantation (AII)
 Antiviral prophylaxis is preferred for patients at high risk of
CMV disease (lung and intestinal transplant recipients, CMV
D+/R patients, and patients receiving therapy with lym-
phocyte-depleting antibodies) (AII)
 The minimum duration of antiviral prophylaxis should be 6–
12 months for lung and intestinal transplantation and 3–
6 months forD+/R kidney, heart and liver transplantation (AII)
 Detecting CMV-speciﬁc cell-mediated immunity can identify
patients at reduced risk of CMV replication and disease (BII)
 Valganciclovir or intravenous ganciclovir are recommended
as ﬁrst-line treatment (AI). Valganciclovir is preferred,
except in cases of life-threatening disease and in situations
where oral intake may not be appropriate (AII). Sequential
therapy (starting with i.v. ganciclovir followed by valganci-
clovir) may be an alternative strategy (BII)
 Ganciclovir resistance should be suspected when persis-
tence of or increase in viral load or clinical progression of
CMV disease is detected despite adequate exposure to the
drug after 3 weeks (AII)
 Foscarnet is the empirical alternative antiviral treatment in
the presence of serious CMV disease and suspected
ganciclovir resistance provided no genotypic study is avail-
able (AII)
 Genotypic determination of resistance is advisable to better
guide treatment (AII)
Human cytomegalovirus (CMV) is a b herpes virus, which
infects about 30–80% of the general population in Europe [1].
Following primary infection, CMV persists as a latent,
non-replicative infection in long-lived cells derived from the
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haematopoietic lineage [2]. Presumably, CMV has co-evolved
with the human species and developed mechanisms to avoid
its immunological elimination. CMV encodes proteins
down-regulating human MHC class I molecules to decrease
recognition and elimination by CD8+ T cells, and avoids lysis
by NK cells through the expression of viral MHC class I
homologue [3].
Although the human immune system cannot eliminate CMV
infection, it is capable of controlling CMV replication and its
pathological effects. Longitudinal studies in kidney transplant
recipients revealed that CMV-speciﬁc T cells emerge early
after the initial viral burst and acquire their stable phenotype in
the months following primary infection [4,5]. CMV-speciﬁc
CD8+ T cells differentiate into memory-effector cells as
characterized by the successive loss of expression of CD45RA,
CCR7, CD27 and CD28, followed by re-expression of
CD45RA. In all stages, these CMV-speciﬁc T cells are able to
lyse target cells in an antigen-speciﬁc manner, as indicated by
the production of interferon-c (IFN-c) and presence of
perforin.
In asymptomatic patients, CMV-speciﬁc CD4+ T cells are
the ﬁrst to appear in the circulation, followed by CMV-speciﬁc
CD8+ T cells and antibody responses. Actually, late emergence
of circulating IFNc-producing CMV-speciﬁc CD4+ T cells
appeared to be predictive for the development of CMV disease
[4].
Latent infection is accompanied by a strong increase in the
number of resting, effector-type CD4+ and CD8+ T cells with
constitutive cytolytic activity in the circulation, but not in the
lymph nodes [6]. A number of functional characteristics of
these cells, speciﬁcally cytotoxicity, IFNc-production and
migratory potential are already detectable during the primary
expansion of this population, a process likely to be governed
by the early and lasting changes in transcription factor
expression [7].
The crucial role of T cells in the defence against the virus is
illustrated by the occurrence of increasing viral replication
leading to organ-invasive, even life-threatening disease, in
solid-organ transplant (SOT) recipients during treatment with
immunosuppressive drugs, in particular with anti-T-cell agents
and/or antiproliferative drugs like mycophenolic acid deriva-
tives [8]. In contrast, treatment with mTOR inhibitors seems
to decrease the incidence of CMV replication or CMV disease,
when compared with other immunosuppressive drug regimens
[9]. The introduction of a CMV vaccine that protects against
symptomatic CMV replication and disease, but does not induce
the strong effector T-cell increase seen in natural CMV
infection, might be an interesting option. However, the strong
heterogeneity in CMV T-cell response at the clonal level [10]
suggests that the design of a vaccine aimed at inducing a T-cell
response able to completely suppress viral replication will be
challenging.
Diagnostic Aspects
Pre-transplant CMV assessment
CMV-speciﬁc antibody testing of donor and recipient is the key
diagnostic assay pre-transplantation to enable risk stratiﬁcation
of CMV replication and disease post-transplantation. CMV-spe-
ciﬁc immunoglobulin-G (IgG) is measured using ELISA tech-
niques, and values above the cut-off are considered as positive
[11–13]. ForCMV-IgG results below the cut-off, a negativeCMV
serostatus is assigned. Administration of intravenous immuno-
globulin (IVIG) preparations can result in positive CMV serology
results. Similarly, CMV antibody responses may be positive in
children <18 months due to transplacental transfer of IgG from
their mothers. In general, repeat serological testing should be
considered when a CMV-negative IgG result has been obtained
more than 2 months before transplantation. Similarly, repeat
testing should be considered if CMV-speciﬁc IgG results are in
the indeterminate zone of the assay, if there is the sole presence
of CMV IgM, or if passive IgG transfer is suggested either
transplacentally or post-infusion. If repeat testing is not possible,
or if the same result is obtained, the donor or recipient should
be assigned to the higher risk category andmanaged accordingly.
Thus, the equivocal IgG result places a donor into the
CMV-infected (CMV +) category, but a recipient into the
CMVnon-infected (CMV) category, except when the donor is
seronegative, in which case we should consider the recipient as
seropositive. Measuring CMV-speciﬁc T cells in blood or testing
for CMV DNA in blood or urine have been proposed as
alternative tests for the pre-transplant assignment [14]. How-
ever, larger studies are lacking that speciﬁcally address this issue
in clinical practice, and a negative result of these tests is unlikely
to reliably rule out latent, persistent or de novoCMV infection in
the respective donor or recipient.
Post-transplantation detection of CMV replication
Recognition of post-transplantation ongoing viral replication
could be achieved by nucleic acid ampliﬁcation testing (NAT)
in a quantitative format, by direct antigen detection (DAD) in
blood (antigenaemia), in bronchoalveolar lavage (BAL) or
tissue samples, or by virus isolation by culture (VIC), which is
typically conﬁrmed with in situ hybridization for CMV DNA or
DAD for CMV pp72 antigen. All of these techniques may have
some relevance in the diagnostic work-up of SOT patients
post-transplant. In recent years, however, quantitative NAT in
blood and immunohistochemistry for CMV antigens have
emerged as key techniques for surveillance, diagnosis and
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follow-up of SOT recipients with asymptomatic or pre-symp-
tomatic CMV replication, and the diagnosis of probable and
proven CMV disease to mandate the administration of antiviral
therapy.
Because of poor inter-laboratory and limited intra-labora-
tory agreement, antigenaemia is no longer regarded as a
preferred technique, while the use of quantitative NAT
calibrated to an international WHO standard and expressed
as international units (IU)/mL is strongly recommended
[15,16]. This will allow for reproducible CMV load results in
blood (CMV viraemia or DNAemia) across different transplant
centres and laboratories, and permit better deﬁnition and
clinical validation of generally accepted laboratory trigger
points for beginning and ending antiviral treatment [17–20].
There are unresolved issues such as the use of plasma vs.
whole blood, the use of BAL and tissue specimens with respect
to thresholds, the identiﬁcation of CMV disease, and the
corresponding need for antiviral treatment.
Diagnosis of post-transplant organ-invasive CMV disease
Immunohistochemistry is the key technique to diagnose
organ-invasive CMV disease. The high speciﬁcity is comple-
mented by a signiﬁcant sensitivity in the case of CMV colitis if
appropriate clinical biopsies are taken [21]. In fact, proven
CMV colitis with undetectable CMV DNAemia is not
infrequently encountered, but this issue needs to be re-eval-
uated using improved calibrated NAT assays.
Detection of virus-speciﬁc T-cell responses
Measurement of CMV-speciﬁc T-cell responses is obtained by
quantifying the number of cytokine-producing T cells after
stimulation with speciﬁc viral epitopes using enzyme-linked
immunospot assay or intracellular cytokine staining and ﬂow
cytometry [22–25]. Published studies suggest that the pres-
ence of CMV-speciﬁc T cells in the peripheral blood is
associated with protection from viral replication and disease.
Similar to the quantitative NAT, however, the comparison
between different assays and antigens is limited, and a
prospective clinical evaluation in an intervention trial is
lacking.
Risk Factors
The most important risk factor for the development of CMV
disease in SOT recipients is mismatching CMV serology
(positive donor and negative recipient), which confers more
than 50% risk of developing CMV disease in the absence of
antiviral prophylaxis or preemptive treatment strategies.
Other risk factors for CMV disease in SOT recipients are
related to the use of speciﬁc immunosuppressive therapy, the
type of transplanted organ, or certain immunological charac-
teristics of donors and recipients (Table 1) [26–39].
Prevention of CMV Disease
Prevention of CMV disease is based on antiviral drugs
administered as universal prophylaxis or preemptive therapy
[40]. Preemptive therapy is uniquely exploited in the setting of
CMV infection, with the aim of aborting the progression of
asymptomatic infection into CMV disease.
TABLE 1. An evidence-based grading classiﬁcation of risk factors for the development of CMV disease in solid organ transplant
recipients
Risk factor
Quality of
evidence Comments
D+/R I Increased risk of CMV replication and disease exceeds 50%. In D+/R+ and D/R+ situations without prophylaxis it is
about 15–20%. In D/R combinations the risk of CMV replication and disease is very low
Use of OKT3/ATG I Use associated with higher risk of CMV replication and disease. Targeted antiviral prophylaxis decreased the risk of CMV
disease in patients who received these drugs
Acute graft rejection I Increased risk of CMV replication and disease due to proinﬂammatory cytokines and subsequent anti-rejection treatment
Use of MMF II Associated with higher risk when MMF dose >2 g/daily. MMF has been particularly linked to the development of CMV
gastrointestinal disease in kidney transplant recipients
Alemtuzumab II Associated with higher risk when the drug is used for rejection treatment, but not when used for induction of
immunosuppressive therapy
Use of mTOR inhibitors II Associated with a lower risk of CMV disease
Type of transplanted organ II Decreasing risk according to small-bowel > lung > pancreas > heart > liver/kidney
Viral co-infection (HHV-6) II Increased risk of CMV disease in the early post-transplant period of liver and kidney transplant recipients
Hypogammaglobulinaemia II Increased risk of CMV disease in heart and kidney transplant recipients
TLR2 and TLR4 polymorphisms II Increased risk factors for Toll-like receptor polymorphisms for CMV disease in renal transplant patients
Low levels of MBL II Increased risk of MBL gene polymorphisms for CMV disease in kidney transplant recipients
Mixed infections caused by
different CMV-gB/gH genotypes
II Increased CMV replication and CMV disease in SOT recipients when different gB/gH genotypes are co-detected
Post-transplant serum Interferon
c levels following ‘in
vitro’ stimulation with CMV antigens
II Reduced risk of patients with detectable CMV-speciﬁc T-cell responses for CMV replication and disease as measured by
interferon-c release assay or intracellular cytokine staining
D+/R, donor CMV-seropositive, recipient CMV-seronegative; ATG, anti-thymocitic globulin; MMF, mofetil mycophenolate; TLR, Toll-like receptors; MBL, mannose-binding
lectine; gB, glycoprotein B; gH, glycoprotein H. [26–39].
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There are few studies that have directly compared
preemptive therapy with universal prophylaxis, so there is an
open debate about the advantages and disadvantages of each
approach. Results from several meta-analyses (including differ-
ent transplant populations, antiviral drugs and immunosup-
pressive regimens) have basically shown that the incidence of
CMV disease is signiﬁcantly reduced (by c. 70%) with both
approaches [44,45]. In one meta-analysis, both prophylaxis and
the preemptive approach reduced the risk of rejection,
although only universal prophylaxis signiﬁcantly reduced the
risk of bacterial and fungal infections and death [41].
Randomized controlled trials comparing both approaches
generally have included a limited number of patients. Khoury
et al. [42] did not observe differences in the incidence of
CMV disease between the valganciclovir prophylaxis and the
preemptive approach in 98 kidney transplant recipients,
including the subgroup of patients at high risk. Kliem et al.
[43] compared ganciclovir prophylaxis with intravenous
ganciclovir preemptive therapy in 148 renal transplant recip-
ients, noting an increased frequency of CMV infection and
disease in the preemptive group. Of note, graft survival at
4 years was lower in the group that developed CMV infection
and received preemptive therapy. Recently, an observational
nationwide cohort study in Switzerland compared both
strategies in more than 1200 SOT recipients [44]. While
the incidence of CMV disease was similar in both groups,
patients who received antiviral prophylaxis had better
graft-failure-free survival, due to a better control of ear-
ly-onset CMV viraemia.
In summary, while both preventive approaches can effec-
tively reduce the incidence of CMV disease after transplanta-
tion, universal prophylaxis has some advantages as it is easier
to implement and may better prevent the occurrence of
indirect effects, by reducing the burden of CMV viraemia.
However, side-effects such as renal toxicity, bone marrow
suppression and costs for patients who may never develop
CMV replication and disease are the downsides of universal
prophylaxis. Preemptive therapy can reduce the cost and
toxicity of antiviral drugs, and may allow the development of
speciﬁc cell-mediated immunity by preventing the development
of late-onset CMV disease [45]. However, the preemptive
approach depends on close monitoring of viral replication and
adequate clinical interpretation and response, and therefore
depends on the existence of adequate diagnostic and medical
logistics in the transplant programme.
Our recommendations support the use of a prophylactic
approach for those patients at high risk of CMV disease, such
as lung and intestinal transplant recipients, D+/R patients and
patients who received lymphocyte-depleting antibodies, in
whom any mistake in the essential surveillance for preemptive
therapy could result in the development of CMV disease
(Table 2).
Despite signiﬁcant improvements in the prevention of CMV
disease, it is desirable to further reduce the burden of CMV
infection with the aim of improving the long-term allograft
outcomes. Two recent randomized controlled trials have
shown that extending the duration of prophylaxis from the
standard 3–6 months (D+/R kidney transplant recipients)
and 12 months (all lung transplant recipients) [46,47] is
associated with a much lower incidence of CMV disease.
However, not all transplant programmes have accepted
6 months of prophylaxis as the standard of care, due to
concerns regarding costs and toxicity [48]. The use of antiviral
prophylaxis followed by screening for CMV replication may
improve the detection of patients at risk of late-onset CMV
disease [49]. However, there is little evidence for recom-
mending its general use. Another approach is to measure the
speciﬁc cell-mediated immunity against CMV in order to
stratify patients according to the individual risk of subsequently
developing late-onset CMV disease. An earlier study identiﬁed
a threshold of 0.03% pp65-speciﬁc CD4+ T cells as protective
against CMV replication in the following 8 weeks. A recent
study showed that developing a positive CMV CD8+ T-cell
response at the discontinuation of prophylaxis predicted
protection against CMV disease [25]. Another study in
CMV-seropositive SOT recipients found that patients without
a detectable pre-transplant cell-mediated immunity had a
higher incidence of post-transplant CMV replication [14].
However, the positive predictive value of detecting CMV-spe-
ciﬁc T cells for protection has been good, ranging from 70% to
>90%, but the negative predictive value has been typically
poor, being <50%. Moreover, the clinically relevant cut-offs
have not been deﬁned in prospective studies. Interventional
studies are needed to identify the optimal time-point, cut-offs
and assays before introducing the cell-mediated immunity
assays into routine clinical practice.
TABLE 2. Recommendations for prevention of CMV disease
in solid organ transplant recipients
Antiviral prophylaxis or preemptive therapy should be used for the prevention of
CMV replication and disease after solid organ transplantation. Grade: AII
Antiviral prophylaxis is preferred for patients at high risk of CMV disease, such as
lung and intestinal transplant recipients, CMV D+/R patients, and SOT patients
receiving induction or rejection therapy with lymphocyte-depleting antibodies.
Grade: AII
The minimum duration of antiviral prophylaxis should be 6–12 months for lung
and intestinal transplantation and 3–6 months for D+/R kidney, heart and liver
transplantation. Grade: AII
When a preemptive approach is used, monitoring of CMV viral load in peripheral
blood should be done every 1–2 weeks during the ﬁrst 3 months post-transplant.
AII. More frequent testing (i.e. twice weekly) may be considered in patients at
high-risk (i.e. D+/R patients, early post-transplant and following use of
lymphocyte-depleting antibodies). Grade: BII
An approach based on antiviral prophylaxis followed by the preemptive strategy
may e used in high-risk patients. Grade: BIII
Detecting CMV-speciﬁc cell-mediated immunity can identify patients at reduced
risk of CMV replication and disease. Grade: BII
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Treatment of CMV Disease
Intravenous (IV) ganciclovir has been the standard treatment
for cytomegalovirus (CMV) in SOT recipients, for both adults
and children (Table 3). An international, multicentre trial
showed that oral valganciclovir was similar in efﬁcacy and
safety to IV ganciclovir in the treatment of CMV disease in a
population of patients with SOT [50,51]. During long-term
follow-up, clinical and virological recurrence was not signiﬁ-
cantly different between groups. However, this study had the
following limitations. The majority of the patients were kidney
transplant recipients, paediatric patients were not included
and, generally, serious or life-threatening CMV disease was not
included. Unfortunately, valganciclovir for treatment of CMV
disease has not been validated by studies in children.
Hence, the drugs recommended for ﬁrst-line treatment of
mild to moderate CMV disease are oral valganciclovir at doses
of 900 mg/12 h or IV ganciclovir at doses of 5 mg/kg/12 h,
dose-adjusted to renal function. In patients with severe,
life-threatening disease and when oral valganciclovir is poorly
tolerated or oral drug absorption may not be appropriate,
intravenous ganciclovir should be used. Sequential therapy
(starting treatment with IV ganciclovir followed by oral
valganciclovir once improvement is initiated) is a potential
therapeutic modality that has, however, not been extensively
evaluated. This pragmatic approach provides an effective
therapy with appropriate drug exposure, reduces treatment
costs and avoids prolonged hospitalization [52].
It is important to administer appropriate doses of both
valganciclovir and ganciclovir. Suboptimal doses can cause lack
of drug efﬁcacy and promote the development of resistance
[53], while supratherapeutic doses favour the appearance of
adverse effects. Glomerular ﬁltration rate should be estimated/
followed during antiviral treatment. The dose and timing of
antiviral drugs should be adjusted according to the estimated
creatinine clearance values as shown in Table 4.
Should leukopenia occur, the differential diagnosis includes
not only potentially myelotoxic drugs such as ganciclovir,
valganciclovir, mycophenolic acid derivatives, mTOR inhibitors
(sirolimus and everolimus), azathioprine and trimethoprim-sul-
phamethoxazole, but also the direct effects of signiﬁcant CMV
replication. Careful consideration of the potential myelotoxic
drugs and the viral replication dynamics should lead to a
judicious decision about lowering or discontinuing drugs
without compromising antiviral treatment and increasing the
risk of emergence of drug-resistant CMV. In severe leukope-
nia, especially if absolute neutrophil count is <1000/lL, the use
of granulocyte colony stimulating factor (G-CSF) may be
considered.
The optimum duration of the treatment of CMV disease
should be individualized based on clinical follow-up and viral
load monitoring. Determinations should be performed weekly
for antigenaemia or viral load by real-time quantitative PCR.
Although both techniques have similar speciﬁcity, >90%, PCR
is preferred in view of a better sensitivity (94% vs. 27%) [54].
Treatment should be maintained until a determination of
antigenaemia or viral load becomes lower than the test’s lower
limit of quantiﬁcation or negative. In high-risk patients it is
preferable to conﬁrm two consecutive negative determina-
tions with a 1-week interval between them to ensure the
clearance of the virus. In any case, the minimum duration of
treatment must never be <2 weeks [55]. A recent study has
proved that patients with a pretreatment viral load lower than
18 200 IU/mL resolve CMV disease more rapidly than those
TABLE 3. Recommendations for the treatment of CMV
disease in solid organ transplant recipients
Valganciclovir or intravenous ganciclovir are recommended as ﬁrst-line treatment.
Grade: AI.
Valganciclovir is preferred except in cases of life-threatening disease and in
situations where oral intake may not be appropriate. Grade: AII.
Sequential therapy (starting with IV ganciclovir followed by valganciclovir) may
be an alternative strategy. Grade: BII.
Antiviral dose adjustment should be performed based on renal function by
Cockroft-Gault formula. Grade: AI.
Dose reduction of valganciclovir and ganciclovir due to adverse events should be
avoided due to risk of resistance. Grade: AIII.
The addition of G-CSF should be considered before cessation of antiviral therapy
in cases of severe leukopenia. Grade: BIII.
Laboratory monitoring of CMV should be performed weekly during the treatment
phase to monitor response. Grade: AII.
Treatment should be continued until viral eradication is achieved at least on one
assay after a minimum of 2 weeks. Grade: AII.
Secondary prophylaxis is not routinely recommended. Grade: CIII.
Dose reduction of immunosuppressive therapy should be considered in severe
CMV disease, in non-responding patients, in patients with high viral loads and
those with leukopenia. Grade: AIII.
Intravenous immunoglobulin may be considered for severe forms of CMV disease
such as pneumonitis. Grade: BII.
Ganciclovir resistance should be suspected when persistence of or increase in viral
load or clinical progression of CMV disease is detected despite adequate
exposure to the drug after 3 weeks. Grade: AII.
Foscarnet is the empirical alternative antiviral treatment in the presence of serious
CMV disease and suspected ganciclovir resistance provided no genotypic study is
available. Grade: AII.
Genotypic determination of resistance is advisable to better guide treatment.
Grade: AII.
TABLE 4. Dosing of ganciclovir and valganciclovir for treat-
ment of CMV disease in SOT recipients based on creatinine
clearance. [11–13]
Creatinine
clearance
(mL/min) IV ganciclovir Valganciclovir
>70 5 mg/kg/12 h 900 mg/12 h
60–69 2.5 mg/kg/12 h 900 mg/12 h
50–59 2.5 mg/kg/12 h 450 mg/12 h
40–49 1.25 mg/kg/12 h 450 mg/12 h
25–39 1.25 mg/kg/12 h 450 mg/day
10–24 0.625 mg/kg/12 h 450 mg/48 h
<10 0.625 mg/kg 3 times per week
(after haemodialysis)
200 mg 3 times per week
(after haemodialysis)a
aUsing powder for oral suspension.
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with a higher viral load, and conﬁrmed the direct association
between viral suppression below the test’s lower limit of
quantiﬁcation and disease resolution [56]. With this therapeu-
tic regimen, the risk of development of resistance and
recurrence of CMV disease is very low.
A concomitant reduction of immunosuppressive therapy
should be considered in the presence of CMV disease. This
decision should be individualized and particularly considered in
the presence of severe CMV disease in neutropenic patients,
in disease with high viral load and when there is a lack of
clinical response to antiviral treatment. An adequate immu-
nosuppressive treatment should be restored when clinical and
virological response is achieved but, as far as possible, the
level of immunosuppression should be lower because the
return to previous values can lead to CMV disease recur-
rence.
The role of immunoglobulins in the treatment of CMV
disease is not well deﬁned, but their use is deemed comple-
mentary in severe inﬂammatory forms of the disease such as
pneumonitis.
The association of ganciclovir and foscarnet, in the absence
of demonstrated ganciclovir resistance, adds no advantages to
monotherapy but greater toxicity [57].
Treatment against Ganciclovir-Resistant
CMV
The emergence of ganciclovir-resistant CMV is a clinical
challenge associated with high morbidity and mortality. Its
incidence may be as high as 13% in lung and in combined
kidney-pancreas transplant recipients [54]. Risk factors for
development of resistance to ganciclovir are D+/R serosta-
tus, pancreas and lung transplantation, serious invasive disease
and/or high viral load, concomitant intense immunosuppressive
treatment, exposure to suboptimal ganciclovir levels, and
prolonged antiviral therapy [58].
In practice, ganciclovir resistance should be suspected when
persistence of or increase in viral load or progression to
clinical CMV disease is detected despite adequate exposure to
the drug for 2 weeks. The antiviral treatment may be
insufﬁcient to suppress viral replication without phenotypic
or genotypic virological resistance when certain host factors
are present, such as severe concomitant immunosuppressive
therapy or hypogammaglobulinaemia.
There are no data from controlled clinical trials showing the
best alternative to treat ganciclovir-resistant CMV disease. So,
empirical alternative antiviral treatment in the presence of risk
factors or serious CMV disease would consist of adding, or
replacing ganciclovir with, foscarnet [59].
Lastly, treatment decisions will be taken depending on the
genotypic analysis of UL97 and UL54 genes. If genotypic
resistance tests show a high mutation resistance in the UL97
gene (mutations M460V/I, A594V, L595S or C603W, which
confer enhanced resistance to ganciclovir more than ﬁve times
the IC50) or UL54 gene (which confers cross-resistance to
ganciclovir and cidofovir) ganciclovir will be changed to
foscarnet. Other mutations in the UL97 gene could be treated
by increasing the dose of ganciclovir up to 10 mg/kg every
12 h.
Cidofovir is not recommended unless the disease is not
clinically severe and mutation in the UL54 gene is ruled out.
No data are available regarding the development of
ganciclovir resistance in children.
Other Antiviral Drugs
Maribavir is an oral potent inhibitor of CMV UL97 kinase.
Unlike ganciclovir, it produces no myelotoxicity and
nephrotoxicity. A phase III trial is ongoing to show its
efﬁcacy in treating CMV infection compared with valganci-
clovir.
An oral derivative of cidofovir (CMX-001) has proved
recently its effectiveness in a phase II trial to prevent CMV
disease in HSCT recipients [60]. It avoids the nephrotoxicity of
cidofovir, with diarrhoea as the most frequent adverse event.
Letermovir inhibits CMV UL56 terminase. Its antiviral effect
was reported in a phase II trial of prophylaxis in HSCT
recipients [61].
Sirolimus and everolimus are immunosuppressive drugs that
act by blocking signal transduction of growth factors. Several
studies with these drugs have shown a lower incidence of CMV
disease [37]. Therefore, it has been proposed to convert
immunosuppression from anticalcineurin inhibitors to mTOR
inhibitors in cases of recurrent or ganciciclovir-resistant CMV
disease.
Some other drugs have been used as potentially effective
agents against resistant or recurrent CMV such as leﬂunomide
and artesunate. At present, data to justify the use of these
drugs are scarce and anecdotal.
Passive immunotherapy with anti-CMV-speciﬁc immune
globulin has been employed in an attempt to improve the
immune status of the host against this virus. Similarly, the
adoptive transfer of T cells speciﬁc for CMV, obtained directly
from immunized donors, or after extraction and ex vivo
expansion, has been evaluated in the treatment of CMV
disease. Clinical trials to evaluate the safety and efﬁcacy of the
transfer of speciﬁc T lymphocytes against CMV are currently
active.
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